Universal Beteiligungs und Servicegesellschaft mbH Sells 4,979,945 Shares of Insulet Corporation $PODD

Universal Beteiligungs und Servicegesellschaft mbH decreased its holdings in shares of Insulet Corporation (NASDAQ:PODD) by 97.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 124,961 shares of the medical instruments supplier’s stock after selling 4,979,945 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned about 0.18% of Insulet worth $38,579,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. True Wealth Design LLC raised its position in shares of Insulet by 288.0% during the 3rd quarter. True Wealth Design LLC now owns 97 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 72 shares in the last quarter. Golden State Wealth Management LLC increased its stake in Insulet by 202.9% during the second quarter. Golden State Wealth Management LLC now owns 103 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 69 shares during the last quarter. Trust Co. of Toledo NA OH bought a new stake in Insulet during the second quarter worth approximately $35,000. Quent Capital LLC purchased a new stake in Insulet during the third quarter valued at approximately $49,000. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Insulet in the 2nd quarter valued at approximately $51,000.

Insulet Stock Performance

Insulet stock opened at $284.96 on Thursday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 2.18 and a current ratio of 2.87. The company has a market capitalization of $20.05 billion, a PE ratio of 82.60, a P/E/G ratio of 1.58 and a beta of 1.40. The company has a 50 day moving average price of $300.76 and a 200-day moving average price of $310.57. Insulet Corporation has a fifty-two week low of $230.05 and a fifty-two week high of $354.88.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $1.24 EPS for the quarter, topping the consensus estimate of $1.13 by $0.11. The company had revenue of $521.70 million for the quarter, compared to the consensus estimate of $678.70 million. Insulet had a return on equity of 24.36% and a net margin of 9.76%.Insulet’s quarterly revenue was up 29.9% on a year-over-year basis. During the same period last year, the business posted $1.08 EPS. As a group, equities analysts forecast that Insulet Corporation will post 3.92 earnings per share for the current year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on PODD shares. UBS Group reissued a “buy” rating on shares of Insulet in a research report on Thursday, December 18th. Raymond James Financial lifted their price objective on shares of Insulet from $366.00 to $385.00 and gave the stock an “outperform” rating in a research note on Friday, November 21st. BTIG Research boosted their price objective on shares of Insulet from $370.00 to $380.00 and gave the company a “buy” rating in a research report on Friday, November 21st. Royal Bank Of Canada raised their target price on shares of Insulet from $370.00 to $380.00 and gave the stock an “outperform” rating in a report on Friday, November 21st. Finally, Sanford C. Bernstein dropped their price target on shares of Insulet from $410.00 to $380.00 and set an “outperform” rating for the company in a research note on Friday, January 9th. Twenty-one analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $379.10.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.